1. Of the ECHO Trial subjects who experienced at least one adverse event, what was the median duration of time from the start of treatment to their first post-dose adverse event?
   1. Assume adverse events with unknown start day began on the 15th of the month.
   2. Assume adverse events that began on the date of first dose occurred after dosing.
   3. Compute durations of time using the +1 convention so that events occurring on the date of first dose have a duration of 1 day.
2. For each treatment group, report the percentage of ECHO trial subjects that had a post-treatment adverse event within 21 days of starting treatment (with the date of first dose corresponding to day 1).
   1. Assume adverse events with unknown start day began on the 15th of the month.
   2. Assume adverse events that began on the date of first dose occurred after dosing.
   3. Assume adverse events that began on the date of first dose occurred after dosing.
3. To be included in this analysis, a subject’s systolic and diastolic blood pressure (BP) values at week 0 must have been greater than 130 and 90, respectively. For each treatment group (restricted to the subjects meeting the above criteria), report the percentage of subjects with either a systolic BP less than 130 or a diastolic BP less than 90 at week 32.